FcRn Portfolio

About Viridian Therapeutics

Viridian Therapeutics is dedicated to framing the future of autoimmune disease treatment by developing optimized therapeutics for rare conditions. The company's core strategy centers on its antibody discovery and engineering platform, with a lead focus on Thyroid Eye Disease (TED) and a broader portfolio targeting the neonatal Fc receptor (FcRn). As a public company, Viridian is advancing its clinical-stage pipeline with the goal of improving patient care in areas of high unmet medical need.

Therapeutic Areas